210 related articles for article (PubMed ID: 24206578)
1. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Ono T; Takeshita A; Kishimoto Y; Kiyoi H; Okada M; Yamauchi T; Emi N; Horikawa K; Matsuda M; Shinagawa K; Monma F; Ohtake S; Nakaseko C; Takahashi M; Kimura Y; Iwanaga M; Asou N; Naoe T;
Cancer Sci; 2014 Jan; 105(1):97-104. PubMed ID: 24206578
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
[TBL] [Abstract][Full Text] [Related]
3. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
4. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
[TBL] [Abstract][Full Text] [Related]
6. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
7. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama K; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake S; Suzushima H; Emi N; Ohno R
J Clin Oncol; 1998 Jan; 16(1):78-85. PubMed ID: 9440726
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
10. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
[TBL] [Abstract][Full Text] [Related]
11. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Tallman MS; Kim HT; Montesinos P; Appelbaum FR; de la Serna J; Bennett JM; Deben G; Bloomfield CD; Gonzalez J; Feusner JH; Gonzalez M; Gallagher R; Miguel JD; Larson RA; Milone G; Paietta E; Rayon C; Rowe JM; Rivas C; Schiffer CA; Vellenga E; Shepherd L; Slack JL; Wiernik PH; Willman CL; Sanz MA
Blood; 2010 Dec; 116(25):5650-9. PubMed ID: 20858857
[TBL] [Abstract][Full Text] [Related]
12. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.
Micol JB; Raffoux E; Boissel N; Lengliné E; Canet E; Daniel MT; Labarthe Ad; Maarek O; Cassinat B; Adès L; Baruchel A; Degos L; Azoulay E; Dombret H
Eur J Cancer; 2014 Apr; 50(6):1159-68. PubMed ID: 24440088
[TBL] [Abstract][Full Text] [Related]
13. Long-term survey of outcome in acute promyelocytic leukemia.
Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
[TBL] [Abstract][Full Text] [Related]
14. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Lengfelder E; Hanfstein B; Haferlach C; Braess J; Krug U; Spiekermann K; Haferlach T; Kreuzer KA; Serve H; Horst HA; Schnittger S; Aul C; Schultheis B; Erben P; Schneider S; Müller-Tidow C; Wörmann B; Berdel WE; Sauerland C; Heinecke A; Hehlmann R; Hofmann WK; Hiddemann W; Büchner T;
Ann Hematol; 2013 Jan; 92(1):41-52. PubMed ID: 23090499
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.
Ono T; Takeshita A; Kishimoto Y; Kiyoi H; Okada M; Yamauchi T; Tsuzuki M; Horikawa K; Matsuda M; Shinagawa K; Monma F; Ohtake S; Nakaseko C; Takahashi M; Kimura Y; Iwanaga M; Asou N; Naoe T;
Cancer Sci; 2012 Nov; 103(11):1974-8. PubMed ID: 22834728
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Schlenk RF; Germing U; Hartmann F; Glasmacher A; Fischer JT; del Valle y Fuentes F; Götze K; Pralle H; Nerl C; Salwender H; Grimminger W; Petzer A; Hensel M; Benner A; Zick L; Döhner K; Fröhling S; Döhner H;
Leukemia; 2005 Jun; 19(6):978-83. PubMed ID: 15843821
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.
Ito S; Ishida Y; Oyake T; Satoh M; Aoki Y; Kowata S; Uchiyama T; Enomoto S; Sugawara T; Numaoka H; Suzuki K; Murai K
Leuk Lymphoma; 2004 Sep; 45(9):1783-9. PubMed ID: 15223636
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
